News Release

Triple-Negative Breast Cancer Associated with Higher Risk of Local Recurrence

Research from The Cancer Institute of New Jersey Presented at 54th Annual ASTRO Meeting
October 31, 2012

Atif Khan, MDNew Brunswick, N.J. – Research from The Cancer Institute of New Jersey (CINJ) shows that women with triple-negative breast cancer and no more than three positive lymph nodes following a mastectomy have a higher risk of local recurrence than similar women whose disease is not classified as triple-negative. The work will be presented as an abstract during the 54th Annual Scientific Meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week. The Cancer Institute of New Jersey is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (RWJMS).

Triple-negative disease occurs in 10 to 25 percent of all breast cancer cases. Some of the most successful breast cancer therapies target certain receptors (estrogen receptors, progesterone receptors or HER2/neu protein) that may cause cancer to spread. These receptors are absent from triple-negative breast cancer cells, thus making the disease resistant to some of these common treatments.

The implications for women with triple-negative breast cancer and just a few positive lymph nodes following mastectomy remain unclear. Most importantly, it is currently unknown which of these women may benefit from post-mastectomy radiation therapy. That is the aspect on which investigators from The Cancer Institute of New Jersey focused their research.

The researchers retrospectively identified 22 women with no more than three positive lymph nodes who suffered a local recurrence following mastectomy whose initial mastectomy tissue was available for study. None of the patients received radiation treatment following their procedure. These patient specimens were compared to those of 28 women with no more than three positive lymph nodes but no evidence of disease at their last follow-up visit. Controls were matched for age (+/- three years) and follow-up duration (less than five years versus more). Tissue specimens were examined for signs of disease.

What investigators found was that women classified as having triple-negative breast cancer were found to be associated with a higher risk of local recurrence. Conversely, being estrogen-receptor positive, progesterone-receptor positive or a combination of both was strongly associated with a lower risk of local recurrence. Use of chemotherapy was also associated with a lower risk.

"By further defining the risk of local recurrence in women with triple negative breast cancer, clinicians can better determine whether radiation treatment should be part of post-mastectomy therapy," noted the lead author of the research, Atif J. Khan, MD, a radiation oncologist at The Cancer Institute of New Jersey and an assistant professor of radiation oncology at RWJMS.

Along with Dr. Khan, other investigators include: Sarah Milgrom, Memorial Sloan Kettering Cancer Center; Nicola Barnard, RWJMS, Susan A. Higgins, Yale University School of Medicine; Meena Moran, Yale University School of Medicine; Sinae Kim, UMDNJ-School of Public Health; Sharad Goyal, The Cancer Institute of New Jersey and RWJMS; Fatima Al-Faraj, Princess Margaret Hospital; and Bruce G. Haffty, The Cancer Institute of New Jersey and RWJMS.

The work represented by members of The Cancer Institute of New Jersey is among more than 1,800 abstracts being presented at the gathering. As the leading organization in radiation oncology, biology and physics, ASTRO's mission is to advance the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results, and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

The meeting, which is open to registered participants only, ends today.

About The Cancer Institute of New Jersey
The Cancer Institute of New Jersey (www.cinj.org) is the state's first and only National Cancer Institute-designated Comprehensive Cancer Center dedicated to improving the detection, treatment and care of patients with cancer, and serving as an education resource for cancer prevention. Physician-scientists at The Cancer Institute of New Jersey engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support CINJ, call 732-235-8614 or visit www.cinjfoundation.org. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. Follow us on Facebook at www.facebook.com/TheCINJ.

The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: CentraState Healthcare System, JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Somerset Medical Center, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center of Princeton at Plainsboro. *Academic Affiliate

Contact: 
Michele Fisher
Phone: 
732-235-9872